Kohn M, Delord M, Chbat M, Guemriche A, Merabet F, Roupie A-L, Lombion N, Farhat H, Longval T, Cabannes-Hamy A, Lambert J, Marque-Juillet S, Raggueneau V, Osman J, Spentchian M, Rigaudeau S, Rousselot P, Besson C. A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia. Haematologica 2022;107(6):1454-1459; https://doi.org/10.3324/haematol.2021.280026.